Optiscan was featured in Stockhead highlighting its leading role in Australian clinical trials. The article emphasizes Optiscan’s ethical clearance for an in vivo study at the Royal Melbourne Hospital, aimed at enhancing breast cancer surgery through its InVue imaging platform.

Additionally, a separate clinical study in Perth will assess the InVivage device’s application in oral cancer surgery, focusing on improving real-time surgical margin assessment. These trials highlight Optiscan’s commitment to advancing precision surgery and cancer treatment.

Read the full article here.